Design, synthesis and biological evaluation of novel selective PI3Kδ inhibitors containing pyridopyrimidine scaffold
M Ma, Y Feng, SQ Zhang, W Duan, L Gao… - Future Medicinal …, 2023 - Taylor & Francis
Aim: In our study compounds with pyrido [3, 2-d] pyrimidine and pyrido [3, 4-d] pyrimidine
were designed, synthesized and evaluated for their biological activity against hematologic …
were designed, synthesized and evaluated for their biological activity against hematologic …
New pyridopyrimidine derivatives as dual EGFR and CDK4/cyclin D1 inhibitors: synthesis, biological screening and molecular modeling
FMA Krakisha, DIA Othman… - Future Medicinal …, 2024 - Taylor & Francis
Aim: A series of pyridopyrimidine derivatives 5–20 was designed, synthesized and
examined for antitumor activity using four types of malignant cells. Materials & methods …
examined for antitumor activity using four types of malignant cells. Materials & methods …
Discovery of novel pyrido [3, 2‐d] pyrimidine derivatives as selective and potent PI3Kδ inhibitors
H Bai, J Sun, H Lei, SQ Zhang, B Yuan… - Drug Development …, 2023 - Wiley Online Library
The δ isoform of class I PI3K (PI3Kδ) has been shown as a promising target for the treatment
of hematologic malignancies and immune diseases. Herein, a series of pyrido [3, 2‐d] …
of hematologic malignancies and immune diseases. Herein, a series of pyrido [3, 2‐d] …